[How Vif regulates the infectivity of HIV-1].
Takaori-Kondo
Akifumi
A
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo-ku, Kyoto 606-8507, Japan.
D000071480:APOBEC-3G Deaminase; D019380:Anti-HIV Agents; D003564:Cytidine Deaminase; D015195:Drug Design; D016346:Gene Products, vif / Q000502:physiology*; D015497:HIV-1 / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D009700:Nucleoside Deaminases; D011506:Proteins / Q000302:isolation & purification / Q000502:physiology; D012097:Repressor Proteins; D014774:Virulence / Q000235:genetics; D014779:Virus Replication; D054320:vif Gene Products, Human Immunodeficiency Virus
D019380:Anti-HIV Agents; D016346:Gene Products, vif; D011506:Proteins; D012097:Repressor Proteins; D054320:vif Gene Products, Human Immunodeficiency Virus; D009700:Nucleoside Deaminases; D000071480:APOBEC-3G Deaminase; C464924:APOBEC3G protein, human; D003564:Cytidine Deaminase